TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Control Bionics Ltd. ( (AU:CBL) ).
Control Bionics Limited has appointed Stephen Rix as a Non-Executive Director and the new Chairman of the Board. Rix, who has a strong background in governance and growth across various sectors, has been a long-time investor in Control Bionics, bringing valuable experience as the company aims to scale its technology and expand globally. His appointment is expected to support the company’s mission of delivering life-changing technology and accelerating its expansion into new markets and applications.
The most recent analyst rating on (AU:CBL) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Control Bionics Ltd. stock, see the AU:CBL Stock Forecast page.
More about Control Bionics Ltd.
Control Bionics is a medical device company specializing in assistive communication and neurotechnology. With over 20 years of experience, the company develops surface Electromyography (EMG) devices, including the NeuroNode technology, which enables speech and computer-controlled functions through wireless signals. Control Bionics operates in North America, Australia, Singapore, and Japan, and is expanding into new markets with its NeuroStrip technology.
Average Trading Volume: 1,062,519
Technical Sentiment Signal: Buy
Current Market Cap: A$24.04M
Learn more about CBL stock on TipRanks’ Stock Analysis page.